The enantioselective synthesis of natural products of the following type (i) amino acid derivatives, (ii) tetrahydrofolic acid, and (iii) 3-hydroxycarotinoides using optically active transition metal catalysts is reported.
Amino Acid Derivativa
The hydrogenation of dehydroamino acids, such as a-N-acetamidocinnamic acid 1 (Scheme l), can be carried out with Wilkinson-type catalysts at room temperature in methanol solution. No hydrogen pressure is necessary; a blanket of hydrogen is sufficient to guarantee quantitative hydrogenation within hours. The product of addition of hydrogen accross the C=C bond of the substrate 1 yields the product Nacetylphenylalanine 2 (Scheme 1). Achiral Wilkinson catalysts give racemic mixtures, a s frontside and backside attack of the prochiral carbon atom have the same probability. frontside and backside attack are no longer equivalent. Thus, the two enantiomers of N-acetylphenylalanine are formed in ratios different from 5050. 
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In the last two decades a variety of optically active chelate phosphines for the enantioselective hydrogenation of dehydroamino acid derivatives have been reported. They are quantitatively accumulated in the "Handbook of Enantioselective Catalysis with Transition Metal Compounds" (4). A selection of successful optically active phosphines is given in Scheme 2. With Rh or Ru complexes of these ligands, the conversion of dehydroamino acids into amino acids in enantioselectivities close to 100 % is state of the art.
'Jetrahvdrofolic Acid
Folic acid 9 is a vitamin which is reduced enzymatically to tetrahydrofolic acid in the body. In this reduction, the two imino groups of the pteridine system take up four reduction equivalents and a new stereogenic center is formed in 6-position of the pteridine ring. Enzymatic reduction exclusively leads to 6s-configuration. In metabolism, tetrahydrofolic acid is a carrier for C1 fragments, which are bound to N5 of the pteridine ring. These C1 fragments are used in the methylation of functional groups and in the synthesis of the DNA bases.
In the treatment of cancers, such as osteosarcomas, high doses of methotrexate are used, which inhibit the enzyme dihydrofolate reductase. This results in a breakdown of the DNA synthesis, hurting especially fast growing tissues like cancers. To guarantee a minimum of metabolism, the patients have to be treated with leucovorine as a rescue agent. Leucovorine is the Ca salt of the 5-formyl derivative 10 of tetrahydrofolic acid, the formyl group of which functions as the C1 fragment essential in metabolism.
Leucovorine is also used in the treatment of colorectal cancers. In the pharmaceutical industry, leucovorine is synthesized by a hydrogenation of folic acid with Pt and Pd catalysts, respectively, followed by a formylation at N5 (Scheme 3). In this procedure, tetrahydrofolic acid is formed as a 1:l mixture of the isomers 6S,S and 6R,S. Thus, the S-configuration of glutamic acid does not induce an optical induction in the formation of the new stereogenic center at C6 of the pteridine ring. It is with this 1:l mixture 6S.S/6R,S that even today medical doctors work, although it is known that the unnatural 6R.S isomer is only slowly metabolized. It enriches in the central nervous system and leads to intoxications on the long run. The separation of the two diastereoisomers 6S,S and 6R,S is extremely difficult. To synthesize 6S,S-leucovorine by stereoselective hydrogenation of folic acid, at present, is an unsolved problem. With immobilized Rh catalysts containing optically active phosphines we succeeded to get high enrichments of the natural 6S.S-isomers of tetrahydrofolic acid and leucovorine (5).
Folic acid and tetrahydrofolic acid are only soluble in the form of their salts in water; they are insoluble in the usual organic solvents. The hydrogenation product tetrahydrofolic acid is a biomolecule sensitive to air, acids and bases. Up to now, a hydrogenation of folic acid to tetrahydrofolic acid using enantioselective transition metal catalysts was not possible. We found a solution to this problem by an immobilization of the Rhlphosphine catalysts. We dissolve the procatalyst [Rh(cod)C1]2 and the optically active phosphine in methylenechloride and add silica. On evaporation of the solvent, a heterogeneous catalyst is obtained, the Wphosphine load of which is insoluble in the buffered aqueous medium used for the hydrogenation of folic acid. The hydrogenation is carried out in an autoclave with 50 bar H2 pressure at 80 'C during 20 hours. After formylation with methyl formate, the analysis of the stereoisomers of leucovorine is achieved by HPLC using a Si02 column, covered with bovine serum albumine. The product ratios 6S,S : 6R,S are strongly dependent on the optically active ligand and on the type of silica used. The best results (above 9O:lO) were obtained with the proline derived optically active ligand BPPM 7 (Scheme 2) and with a silica of extremely homogeneous particle size. 
